Dublin, Ireland, April 13, 2018 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced that preclinical data on IBL-302, a pan-PIM/pan-PI3K/mTOR inhibitor, in breast cancer will be presented at the at the 2018 American Association for Cancer Research (AACR) Annual Meeting, being held April 14-18, 2018 in Chicago.
The data was generated through a collaboration between Inflection Biosciences and RCSI (Royal College of Surgeons in Ireland), led by Professor Bryan Hennessy, Senior Clinical Lecturer at RCSI, a Consultant Medical Oncologist, and Adjunct Professor in the Division of Cancer Medicine at MD Anderson Cancer Centre (MDACC). The collaboration was supported by Enterprise Ireland.
Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences commented “This year’s AACR annual meeting will mark the first presentation of in vivo efficacy data in breast cancer models for our lead molecule IBL-302, a pan-PIM/pan-PI3K/mTOR inhibitor.”
The details for the poster presentations are as follows:
Poster Title: Evaluation of dual-acting PIM/PI3K inhibitor IBL-302 in preclinical breast cancer models
Poster Session Category: Experimental and Molecular Therapeutics / Novel Experimental Combinations
Time & Date: 1.00 pm – 5.00 pm; Monday, April 16, 2018
Presenter: Dr. Sean Kennedy (RCSI)
Abstract Number: 2932
Poster Board Number: 12
Location: McCormack Place South, Exhibit Hall A, Poster Section 41
The full abstract can be viewed here.
About PIM and PI3K in breast cancer
PIK3CA (which encodes the PI3K alpha isoform) is the most frequently mutated oncogene in breast cancer. The high prevalence of cancer-associated PI3K pathway alterations underpins the large number of treatments in development targeting this pathway. However, PI3K inhibitors have only shown clinical efficacy in a limited subset of breast cancer patients with intrinsic and acquired resistance posing a significant challenge. PIM kinase is elevated in triple negative breast cancer and mediates resistance to HER-2 therapies. Recent studies have shown that PIM kinase overexpression confers resistance to PI3K inhibitors in breast cancer cells. Whereas PI3K inhibitors primarily induce cell cycle arrest, leaving a reserve of tumour cells that may acquire or exhibit resistance, PIM suppression drives the cell cycle arrest induced by PI3K inhibition into apoptosis. Therefore, combined PI3K and PIM kinase inhibition represents a synergistic combination with therapeutic potential in breast cancer.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com
Comentarios